PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymoma.
Rare Tumors
; 15: 20363613231152333, 2023.
Article
in English
| MEDLINE | ID: covidwho-2232863
ABSTRACT
Myxopapillary ependymoma (MPE) is a primary tumor of the central nervous system (CNS), characteristically an indolent malignancy involving the spinal conus medullaris, Filum terminale or cauda equina. We present a rare case of MPE, recurrent in the pelvic soft tissue with eventual pleural and intra-pulmonary metastasis. Refractory to repeated gross resection, adjuvant radiotherapy, platinum-based chemotherapy and temozolomide exploitation of mutant somatic BRCA1 status with the addition of a poly (ADP-ribose); polymerase inhibitor (PARPi) in a novel combination regimen with olaparib-temozolomide (OT) has achieved stable radiological disease after 10 cycles.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
Language:
English
Journal:
Rare Tumors
Year:
2023
Document Type:
Article
Affiliation country:
20363613231152333
Similar
MEDLINE
...
LILACS
LIS